Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Depreciation & Amortization (CF) (2020 - 2025)

RxSight's Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $851000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 65.24% year-over-year to $851000.0; the TTM value through Dec 2025 reached $3.3 million, down 8.64%, while the annual FY2025 figure was $3.3 million, 8.64% down from the prior year.
  • Depreciation & Amortization (CF) reached $851000.0 in Q4 2025 per RXST's latest filing, roughly flat from $854000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q3 2024 to a low of $515000.0 in Q4 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $938900.0, with a median of $972000.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): crashed 51.0% in 2024, then soared 65.24% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.0 million in 2021, then decreased by 10.44% to $918000.0 in 2022, then rose by 14.49% to $1.1 million in 2023, then plummeted by 51.0% to $515000.0 in 2024, then skyrocketed by 65.24% to $851000.0 in 2025.
  • Per Business Quant, the three most recent readings for RXST's Depreciation & Amortization (CF) are $851000.0 (Q4 2025), $854000.0 (Q3 2025), and $785000.0 (Q2 2025).